Publications

Pancreatic cancer: a review (vol 326, pg 851, 2021)

W Park, A Chawla, EM O'Reilly

Persistent disparities in treatment and survival for patients with pancreatic cancer despite insurance expansion policies

LV Saadat, JF Chou, M Gonen, KC Soares, VP Balachandran, ...

Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer

Joshi S, Gomes ED, Wang T, Corben A, Taldone T, Gandu S, Xu C, Sharma S, et al.

POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).

LH Schwartz, HL Kindler, P Hammel, M Reni, E Van Cutsem, T Macarulla, ...

POLO: subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer

D Arnold, T Golan, P Hammel, M Reni, E Van Cutsem, T Macarulla, ...

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, Park W, Nadal E, et al.

Preliminary clinical and biologic results of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab, in advanced solid tumors (KEYNOTE A36).

H Park, JC Bendell, WA Messersmith, DW Rasco, JS De Bono, ...

Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery

SM Dickinson, CA McIntyre, JB Schilsky, KA Harrington, SR Gerst, ...

Prognostic value of the Memorial Sloan Kettering Prognostic Score in metastatic pancreatic adenocarcinoma

Lebenthal JM, Zheng J, Glare PA, O'Reilly EM, Yang AC, Epstein AS

Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.

R Cohen, Q Shi, JP Meyers, Z Jin, M Svrcek, CS Fuchs, F Couture, ...

Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib+/-doxorubicin: Correlative science from CALGB 80802 …

L Dercle, SM Geyer, AB Nixon, F Innocenti, Q Shi, SB Jacobson, L Luk, ...

Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial

Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, Meyers MO, Boffa DJ, et al.

Randomized phase II trial of olaparib+ pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (g BRCA …

V Chung, KA Guthrie, MJ Pishvaian, AM Lowy, EG Chiorean, MT Duong, ...

Real-world overall survival of patients diagnosed with recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC).

EM O'Reilly, KH Yu, N Lamarre, A Surinach, P Cockrum

Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with …

V Florou, CS Floudas, A Maoz, AR Naqash, G Hildebrand, E Sokol, ...

Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies

A Hendifar, EM Blais, B Wolpin, V Subbiah, E Collisson, I Singh, ...

Targeting DNA Damage Repair Mechanisms in Pancreas Cancer

Perkhofer L, Golan T, Cuyle PJ, Matysiak-Budnik T, Van Laethem JL, Macarulla T, Cauchin E, Kleger A, et al.

Targeting DNA damage repair pathways in pancreas cancer

Crowley F, Park W, O'Reilly EM

Therapeutic Implications of Germline Testing in Patients With Advanced Cancers

Stadler ZK, Maio A, Chakravarty D, Kemel Y, Sheehan M, Salo-Mullen E, Tkachuk K, Fong CJ, et al.

Treatment patterns and survival in patients with early-onset pancreatic cancer

Saadat LV, Chou JF, Gonen M, Soares KC, Kingham TP, Varghese AM, Jarnagin WR, D'Angelica MI, et al.

1527P Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer: Phase III …

D Hochhauser, H Kindler, P Hammel, M Reni, E Van Cutsem, T Macarulla, ...

388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors

J Bendell, W Messersmith, D Rasco, A Wang-Gillam, W Park, L Zhou, ...

75 Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer

D Bortone, S Vensko, S Entwistle, A Cogdill, A Monette, Y Najjar, R Sweis, ...

A mixed methods analysis of patients’ advance care planning values in outpatient oncology: Person-Centered Oncologic Care and Choices (P-COCC)

R Agarwal, E Shuk, D Romano, M Genoff, Y Li, EM O’Reilly, W Breitbart, ...

A multicenter randomized three‐arm phase II study of (1) everolimus,(2) estrogen deprivation therapy (EDT) with leuprolide+ letrozole, and (3) everolimus+ EDT in patients with …

I El Dika, RJ Mayer, AP Venook, M Capanu, MP LaQuaglia, R Kobos, ...

A phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies.

JC Bendell, GA Manji, S Pant, DW Lai, J Colabella, W Berry, MC Paoloni, ...

A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in …

DW Rasco, JC Bendell, A Wang-Gillam, W Park, EM O'Reilly, L Zhou, ...

A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors

AM Schram, AE Drilon, T Macarulla, EM O'Reilly, J Rodon, BM Wolpin, ...

A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT).

AM Varghese, C Ang, CJ Dimaio, MM Javle, M Gutierrez, N Yarom, ...

A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C)+/-veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g) BRCA/PALB2 …

EM O'Reilly, JW Lee, M Zalupski, M Capanu, J Park, T Golan, E Tahover, ...

A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma

Hayashi A, Fan J, Chen R, Ho YJ, Makohon-Moore AP, Lecomte N, Zhong Y, Hong J, et al.

Abstract CT247: A phase 1/2 study of GB1275, a first-in-class CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with …

A Wang-Gillam, DW Rasco, W Park, E O'Reilly, W Messersmith, ...

Actionable alterations (AA) in gastrointestinal (GI) cancers: Rate of detection and receipt of matched therapies (MT).

M Greally, Y Tuvy, BM Millang, EM O'Reilly, R Yaeger, LB Saltz, GY Ku

Advances in the management of pancreatic adenocarcinoma

EM O’Reilly

Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial

H Algul, M Reni, HL Kindler, P Hammel, E Van Cutsem, T Macarulla, ...

Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial.

M Reni, HL Kindler, P Hammel, E Van Cutsem, T Macarulla, MJ Hall, ...

Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma

McIntyre CA, Lawrence SA, Richards AL, Chou JF, Wong W, Capanu M, … Park W, …

An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice: a review

M Rainone, I Singh, EE Salo-Mullen, ZK Stadler, EM O’Reilly

Artikel online veröffentlicht: 02.11. 2020

EM O’Reilly

Association of coffee intake with survival in patients with advanced or metastatic colorectal cancer

C Mackintosh, C Yuan, FS Ou, S Zhang, D Niedzwiecki, IW Chang, ...

Association of diet quality with survival among people with metastatic colorectal cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial

EL Van Blarigan, S Zhang, FS Ou, A Venlo, K Ng, C Atreya, K Van Loon, ...

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

Park W, Mezquita L, Okabe N, Chae YK, Kwon D, Saravia D, Auclin E, Planchard D, et al.

Author Correction: Tumour lineage shapes BRCA-mediated phenotypes

P Jonsson, C Bandlamudi, ML Cheng, P Srinivasan, SS Chavan, ...

Author Correction: Tumour lineage shapes BRCA-mediated phenotypes (Nature,(2019), 571, 7766,(576-579), 10.1038/s41586-019-1382-1)

P Jonsson, C Bandlamudi, ML Cheng, P Srinivasan, SS Chavan, ...

Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405

Guercio BJ, Zhang S, Venook AP, Ou FS, Niedzwiecki D, Lenz HJ, Innocenti F, Mullen BC, et al.

BReast CAncer Gene (BRCA) Mutations as an Emerging Biomarker for the Treatment of Gastrointestinal Malignancies

N Premnath, EM O’Reilly

Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion

Hilmi M, Nicolle R, Bousquet C, Neuzillet C

Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study

Hilmi M, Ederhy S, Waintraub X, Funck-Brentano C, Cohen A, Vozy A, Lebrun-Vignes B, Moslehi J, et al.

Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial.

M Reni, H Riess, EM O'Reilly, JA Reeves, E Chiorean, TJ George, ...

Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, De Giglio A, et al.